About this trial
The standard method for localizing non-palpable breast cancer is currently preoperative wire-guided localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of wire vs. combined breast tissue markers in localizing non-palpable breast cancer.
Eligibility criteria
Qualifiers
female patients, age≥18 year
A score of ≥ 2 on the Eastern Cooperative Oncology Group scale
Patients pathologically diagnosed with untreated breast cancer by core-needle biopsy, with histologically confirmed non-palpable in situ cancer, including pleomorphic lobular carcinoma in situ or invasive non-palpable breast cancer that required localization
Patients are willing to undergo breast conserving surgery and have no contraindications to breast conserving surgery.
Disqualifiers
Inflammatory breast cancer or Paget's disease
Breast deformities and other conditions that impact breast conservation success rate
Patients with contraindications to breast-conserving surgery, as well as those with systemic diseases, mental disorders, or other subjective reasons that may affect their ability to participate in the trial. Patients with severe bleeding disorders or coagulation disorders were also excluded
Pregnancy or lactation
Trial design
Treatments tested in this trial
- Wire-guided localization and marker clip localization
- Wire-guided localization